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Abstract
© 2016 The Author(s)Previously,  we showed that CD206-targeted liposomal delivery of co-
encapsulated immunodominant myelin basic protein (MBP) sequences MBP46–62, MBP124–139
and MBP147–170 (Xemys)  suppressed experimental  autoimmune encephalomyelitis  in  dark
Agouti rats. The objective of this study was to assess the safety of Xemys in the treatment of
patients with relapsing-remitting multiple sclerosis (MS) and secondary progressive MS, who
failed to achieve a sustained response to first-line disease-modifying therapies. In this phase I,
open-label,  dose-escalating,  proof-of-concept  study,  20  patients  with  relapsing-remitting  or
secondary progressive MS received weekly subcutaneously injections with ascending doses of
Xemys up to a total dose of 2.675 mg. Clinical examinations, including Expanded Disability
Status Scale score, magnetic resonance imaging results, and serum cytokine concentrations,
were assessed before the first injection and for up to 17 weeks after the final injection. Xemys
was safe and well tolerated when administered for 6 weeks to a maximum single dose of 900
μg. Expanded Disability Status Scale scores and numbers of T2-weighted and new gadolinium-
enhancing lesions on magnetic resonance imaging were statistically unchanged at study exit
compared with baseline; nonetheless, the increase of number of active gadolinium-enhancing
lesions on weeks 7 and 10 in comparison with baseline was statistically significant. During
treatment,  the serum concentrations of  the cytokines monocyte chemoattractant protein-1,
macrophage inflammatory protein-1β, and interleukin-7 decreased, whereas the level of tumor
necrosis factor-α increased. These results provide evidence for the further development of
Xemys as an antigen-specific, disease-modifying therapy for patients with MS.
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